- $1.08bn
- $994.26m
- $135.73m
- 70
- 78
- 52
- 78
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.81 | ||
| Price to Tang. Book | 0.81 | ||
| Price to Free Cashflow | 8.77 | ||
| Price to Sales | 7.96 | ||
| EV to EBITDA | 9.17 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.09% | ||
| Return on Equity | 8.1% | ||
| Operating Margin | 79.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 150.89 | 110.01 | 103.86 | 218.14 | 135.73 | n/a | n/a | 6.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +24.7 | -26.33 | -4.88 | +115.81 | -38.07 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioPharma Credit PLC is a United Kingdom-based closed-ended investment company. The principal activity of the Company is to invest in interest-bearing debt assets with a contractual right to future cash flows derived from royalties or sales of approved life sciences products. The Company's investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve its investment objective predominantly through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt and credit linked notes. Its diversified portfolio is primarily secured by cash flows derived from sales of approved life sciences products. The Company holds a majority of its investments through its financing subsidiary, BPCR Limited Partnership. Its investment manager is Pharmakon Advisors L.P.
Directors
- Harry Hyman NEC
- Pedro de Cosio IVM
- Martin Friedman IVM
- Pablo Legorreta IVM (57)
- Colin Bond NID (61)
- Duncan Budge NID
- Stephanie Leouzon NID
- Rolf Soderstrom NID (55)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 24th, 2016
- Public Since
- March 27th, 2017
- No. of Employees
- 11
- Sector
- Collective Investments
- Industry
- Financials
- Exchange
London Stock Exchange- Shares in Issue
- 1,231,842,727
- Address
- 51 New North Road, EXETER, EX4 4EP
- Web
- http://bpcruk.com/#
- Phone
- +44 1392477503
- Auditors
- Ernst & Young
Latest News for BPCR
Upcoming Events for BPCR
BioPharma Credit PLC Annual Shareholders Meeting
BioPharma Credit PLC Annual Shareholders Meeting
Half Year 2024 BioPharma Credit PLC Earnings Release
Similar to BPCR
3i Infrastructure
London Stock Exchange
Aberforth Smaller Companies Trust
London Stock Exchange
Aberforth Split Level Income Trust
London Stock Exchange
Abrdn Asia Focus
London Stock Exchange
abrdn Asian Income Fund
London Stock Exchange
FAQ
As of Today at 19:04 UTC, shares in Biopharma Credit are trading at $0.88. This share price information is delayed by 15 minutes.
Shares in Biopharma Credit last closed at $0.88 and the price had moved by -8.75% over the past 365 days. In terms of relative price strength the Biopharma Credit share price has underperformed the FTSE All Share Index by -8.71% over the past year.
The overall consensus recommendation for Biopharma Credit is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Biopharma Credit dividend yield is 10.27% based on the trailing twelve month period.
Last year, Biopharma Credit paid a total dividend of $0.09, and it currently has a trailing dividend yield of 10.27%.Looking ahead, the next dividend pay date is 2024-04-30.
We do not have data on when Biopharma Credit is to next pay dividends. The historic dividend yield on Biopharma Credit shares is currently 10.27%.
To buy shares in Biopharma Credit you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.88, shares in Biopharma Credit had a market capitalisation of $1.08bn.
Here are the trading details for Biopharma Credit:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: BPCR
Based on an overall assessment of its quality, value and momentum Biopharma Credit is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biopharma Credit. Over the past six months, its share price has underperformed the FTSE All Share Index by -0.59%.
As of the last closing price of $0.88, shares in Biopharma Credit were trading +0.77% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biopharma Credit PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biopharma Credit's management team is headed by:
- Harry Hyman - NEC
- Pedro de Cosio - IVM
- Martin Friedman - IVM
- Pablo Legorreta - IVM
- Colin Bond - NID
- Duncan Budge - NID
- Stephanie Leouzon - NID
- Rolf Soderstrom - NID